Schematic overview of the cellular and molecular mechanisms involved in the cancer progression, including the proposed cellular and molecular mechanisms in cancer cells trajectory. AT1: alveolar type 1 cells; AT2: alveolar type 2 cells; AAH: atypical adenomatous hyperplasia; AIS: adenocarcinoma in situ; MIA: minimally invasive adenocarcinoma; IA: invasive adenocarcinoma; EMT: epithelial-mesenchymal transition

Home

Download

Statistics

Help

Contact

Center for Computational Systems Medicine
leaf

Gene summary

leaf

Malignant transformation analysis

leaf

Malignant transformation related pathway analysis

leaf

Cell-cell communication analysis

leaf

Single-cell gene regulatory network inference analysis

leaf

Somatic mutation of malignant transformation related genes

leaf

Related drugs of malignant transformation related genes

Gene: PRMT1

Gene summary for PRMT1

check button Gene summary.

Gene informationSpeciesHuman
Gene symbol

PRMT1

Gene ID

3276

Gene nameprotein arginine methyltransferase 1
Gene AliasANM1
Cytomap19q13.33
Gene Typeprotein-coding
GO ID

GO:0000165

UniProtAcc

A0A087X1W2


Top

Malignant transformation analysis

check button Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells
check button Malignant transformation involving gene list.
Entrez IDSymbolReplicatesSpeciesOrganTissueAdj P-valueLog2FCMalignancy
3276PRMT1HTA11_3410_2000001011HumanColorectumAD4.03e-072.47e-010.0155
3276PRMT1HTA11_1938_2000001011HumanColorectumAD1.45e-094.72e-01-0.0811
3276PRMT1HTA11_347_2000001011HumanColorectumAD5.16e-072.72e-01-0.1954
3276PRMT1HTA11_3361_2000001011HumanColorectumAD5.54e-033.93e-01-0.1207
3276PRMT1HTA11_83_2000001011HumanColorectumSER1.66e-073.68e-01-0.1526
3276PRMT1HTA11_696_2000001011HumanColorectumAD9.44e-084.36e-01-0.1464
3276PRMT1HTA11_866_2000001011HumanColorectumAD3.37e-021.85e-01-0.1001
3276PRMT1HTA11_1391_2000001011HumanColorectumAD4.86e-197.08e-01-0.059
3276PRMT1HTA11_2992_2000001011HumanColorectumSER8.75e-045.33e-01-0.1706
3276PRMT1HTA11_5212_2000001011HumanColorectumAD5.10e-033.70e-01-0.2061
3276PRMT1HTA11_546_2000001011HumanColorectumAD2.97e-023.33e-01-0.0842
3276PRMT1HTA11_866_3004761011HumanColorectumAD2.31e-235.81e-010.096
3276PRMT1HTA11_8622_2000001021HumanColorectumSER3.08e-034.35e-010.0528
3276PRMT1HTA11_7663_2000001011HumanColorectumSER1.32e-034.34e-010.0131
3276PRMT1HTA11_6801_2000001011HumanColorectumSER7.16e-046.06e-010.0171
3276PRMT1HTA11_10711_2000001011HumanColorectumAD6.00e-094.14e-010.0338
3276PRMT1HTA11_7696_3000711011HumanColorectumAD7.04e-419.40e-010.0674
3276PRMT1HTA11_6818_2000001011HumanColorectumAD1.03e-055.26e-010.0112
3276PRMT1HTA11_7469_2000001011HumanColorectumAD1.71e-045.96e-01-0.0124
3276PRMT1HTA11_6818_2000001021HumanColorectumAD8.61e-104.39e-010.0588
Page: 1 2 3 4 5 6 7 8 9 10 

check button Transcriptomic changes along malignancy continuum.
TissueExpression DynamicsAbbreviation
Colorectum (GSE201348)The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.FAP: Familial adenomatous polyposis
CRC: Colorectal cancer
Colorectum (HTA11)The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.AD: Adenomas
SER: Sessile serrated lesions
MSI-H: Microsatellite-high colorectal cancer
MSS: Microsatellite stable colorectal cancer
EndometriumThe image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.AEH: Atypical endometrial hyperplasia
EEC: Endometrioid Cancer
EsophagusThe image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.ESCC: Esophageal squamous cell carcinoma
HGIN: High-grade intraepithelial neoplasias
LGIN: Low-grade intraepithelial neoplasias
LiverThe image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.HCC: Hepatocellular carcinoma
NAFLD: Non-alcoholic fatty liver disease
Oral CavityThe image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.EOLP: Erosive Oral lichen planus
LP: leukoplakia
NEOLP: Non-erosive oral lichen planus
OSCC: Oral squamous cell carcinoma
ProstateThe image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.BPH: Benign Prostatic Hyperplasia
SkinThe image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.AK: Actinic keratosis
cSCC: Cutaneous squamous cell carcinoma
SCCIS:squamous cell carcinoma in situ
ThyroidThe image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.ATC: Anaplastic thyroid cancer
HT: Hashimoto's thyroiditis
PTC: Papillary thyroid cancer
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.

Top

Malignant transformation related pathway analysis

check buttonFind out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer
check button Figure of enriched GO biological processes.
TissueDisease StageEnriched GO biological Processes
ColorectumADGO analysis - Figure of enriched GO biological processes: Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).
ColorectumSERGO analysis - Figure of enriched GO biological processes: Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).
ColorectumMSSGO analysis - Figure of enriched GO biological processes: Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).
ColorectumMSI-HGO analysis - Figure of enriched GO biological processes: Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).
ColorectumFAPGO analysis - Figure of enriched GO biological processes: Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).
Page: 1 2 3 4 5 6 7 8 9 

check button Enriched GO biological processes.
GO IDTissueDisease StageDescriptionGene RatioBg Ratiopvaluep.adjustCount
GO:0008380ColorectumADRNA splicing169/3918434/187233.59e-182.04e-15169
GO:0034101ColorectumADerythrocyte homeostasis51/3918129/187231.07e-063.59e-0551
GO:0030099ColorectumADmyeloid cell differentiation119/3918381/187231.24e-064.01e-05119
GO:0002262ColorectumADmyeloid cell homeostasis57/3918157/187236.17e-061.56e-0457
GO:0048872ColorectumADhomeostasis of number of cells87/3918272/187231.16e-052.61e-0487
GO:0030218ColorectumADerythrocyte differentiation45/3918120/187232.22e-054.39e-0445
GO:0001701ColorectumADin utero embryonic development110/3918367/187232.36e-054.62e-04110
GO:0051403ColorectumADstress-activated MAPK cascade72/3918239/187234.77e-045.25e-0372
GO:0031098ColorectumADstress-activated protein kinase signaling cascade74/3918247/187234.80e-045.27e-0374
GO:0045646ColorectumADregulation of erythrocyte differentiation20/391847/187236.54e-046.75e-0320
GO:0070302ColorectumADregulation of stress-activated protein kinase signaling cascade58/3918195/187232.21e-031.74e-0258
GO:0032872ColorectumADregulation of stress-activated MAPK cascade57/3918192/187232.51e-031.92e-0257
GO:1903706ColorectumADregulation of hemopoiesis99/3918367/187233.08e-032.28e-0299
GO:0045637ColorectumADregulation of myeloid cell differentiation61/3918210/187233.17e-032.35e-0261
GO:00083801ColorectumSERRNA splicing123/2897434/187233.84e-128.41e-10123
GO:00341011ColorectumSERerythrocyte homeostasis39/2897129/187231.70e-055.11e-0439
GO:00022621ColorectumSERmyeloid cell homeostasis44/2897157/187234.09e-051.03e-0344
GO:00488721ColorectumSERhomeostasis of number of cells65/2897272/187231.70e-043.19e-0365
GO:00302181ColorectumSERerythrocyte differentiation33/2897120/187235.15e-047.30e-0333
GO:00456461ColorectumSERregulation of erythrocyte differentiation16/289747/187231.29e-031.44e-0216
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 

check button Enriched KEGG pathways.
Pathway IDTissueDisease StageDescriptionGene RatioBg Ratiopvaluep.adjustqvalueCount
hsa04922ColorectumADGlucagon signaling pathway41/2092107/84651.18e-037.75e-034.94e-0341
hsa049221ColorectumADGlucagon signaling pathway41/2092107/84651.18e-037.75e-034.94e-0341
hsa049222ColorectumSERGlucagon signaling pathway38/1580107/84652.57e-053.28e-042.38e-0438
hsa049223ColorectumSERGlucagon signaling pathway38/1580107/84652.57e-053.28e-042.38e-0438
hsa049224ColorectumMSSGlucagon signaling pathway39/1875107/84655.00e-043.45e-032.11e-0339
hsa049225ColorectumMSSGlucagon signaling pathway39/1875107/84655.00e-043.45e-032.11e-0339
hsa040689EsophagusESCCFoxO signaling pathway89/4205131/84651.56e-057.98e-054.09e-0589
hsa0492214EsophagusESCCGlucagon signaling pathway64/4205107/84652.18e-024.80e-022.46e-0264
hsa0406814EsophagusESCCFoxO signaling pathway89/4205131/84651.56e-057.98e-054.09e-0589
hsa0492215EsophagusESCCGlucagon signaling pathway64/4205107/84652.18e-024.80e-022.46e-0264
hsa040682LiverCirrhoticFoxO signaling pathway52/2530131/84659.98e-033.32e-022.05e-0252
hsa0492221LiverCirrhoticGlucagon signaling pathway43/2530107/84651.42e-024.35e-022.68e-0243
hsa040683LiverCirrhoticFoxO signaling pathway52/2530131/84659.98e-033.32e-022.05e-0252
hsa0492231LiverCirrhoticGlucagon signaling pathway43/2530107/84651.42e-024.35e-022.68e-0243
hsa040684LiverHCCFoxO signaling pathway85/4020131/84653.99e-052.16e-041.20e-0485
hsa0492241LiverHCCGlucagon signaling pathway64/4020107/84656.70e-031.87e-021.04e-0264
hsa040685LiverHCCFoxO signaling pathway85/4020131/84653.99e-052.16e-041.20e-0485
hsa0492251LiverHCCGlucagon signaling pathway64/4020107/84656.70e-031.87e-021.04e-0264
hsa040688Oral cavityOSCCFoxO signaling pathway85/3704131/84657.50e-074.33e-062.21e-0685
hsa0406813Oral cavityOSCCFoxO signaling pathway85/3704131/84657.50e-074.33e-062.21e-0685
Page: 1 2 

Top

Cell-cell communication analysis

check buttonIdentification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states
LigandReceptorLRpairPathwayTissueDisease Stage
Page: 1 

Top

Single-cell gene regulatory network inference analysis

check buttonFind out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states
TFCell TypeTissueDisease StageTarget GeneRSSRegulon Activity
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression.
Page: 1 

Top

Somatic mutation of malignant transformation related genes

check buttonAnnotation of somatic variants for genes involved in malignant transformation
Hugo SymbolVariant ClassVariant ClassificationdbSNP RSHGVScHGVSpHGVSp ShortSWISSPROTBIOTYPESIFTPolyPhenTumor Sample BarcodeTissueHistologySexAgeStageTherapy TypesDrugsOutcome
PRMT1deletionFrame_Shift_Delc.945delNp.Val316CysfsTer8p.V316Cfs*8protein_codingTCGA-D8-A27V-01Breastbreast invasive carcinomaFemale<65I/IIHormone TherapytamoxiphenSD
PRMT1SNVMissense_Mutationrs544334510c.562N>Ap.Asp188Asnp.D188Nprotein_codingtolerated(0.34)benign(0.007)TCGA-DS-A0VM-01Cervixcervical & endocervical cancerFemale<65I/IIChemotherapycisplatinPD
PRMT1SNVMissense_Mutationc.584G>Ap.Arg195Glnp.R195Qprotein_codingtolerated(0.06)probably_damaging(0.999)TCGA-AD-6895-01Colorectumcolon adenocarcinomaMale>=65III/IVUnknownUnknownSD
PRMT1SNVMissense_Mutationc.896N>Tp.Thr299Ilep.T299Iprotein_codingtolerated(1)benign(0.139)TCGA-CK-4951-01Colorectumcolon adenocarcinomaFemale>=65I/IIUnknownUnknownPD
PRMT1SNVMissense_Mutationc.536N>Gp.Tyr179Cysp.Y179Cprotein_codingdeleterious(0)possibly_damaging(0.837)TCGA-D5-6541-01Colorectumcolon adenocarcinomaMale<65I/IIUnknownUnknownSD
PRMT1SNVMissense_Mutationnovelc.298G>Ap.Gly100Serp.G100Sprotein_codingdeleterious(0.04)benign(0.308)TCGA-A5-A0G2-01Endometriumuterine corpus endometrioid carcinomaFemale<65III/IVUnknownUnknownSD
PRMT1SNVMissense_Mutationnovelc.1015C>Tp.Pro339Serp.P339Sprotein_codingdeleterious(0.03)possibly_damaging(0.822)TCGA-A5-A0GG-01Endometriumuterine corpus endometrioid carcinomaFemale>=65I/IIUnknownUnknownSD
PRMT1SNVMissense_Mutationc.985G>Ap.Glu329Lysp.E329Kprotein_codingdeleterious(0.01)probably_damaging(0.938)TCGA-AP-A0LM-01Endometriumuterine corpus endometrioid carcinomaFemale<65III/IVChemotherapycisplatinSD
PRMT1SNVMissense_Mutationnovelc.90A>Tp.Glu30Aspp.E30Dprotein_codingtolerated(0.43)benign(0.001)TCGA-AX-A06F-01Endometriumuterine corpus endometrioid carcinomaFemale<65III/IVChemotherapycarboplatinSD
PRMT1SNVMissense_Mutationc.1021N>Ap.Ala341Thrp.A341Tprotein_codingtolerated(0.12)benign(0.006)TCGA-AX-A0J1-01Endometriumuterine corpus endometrioid carcinomaFemale>=65I/IIUnknownUnknownSD
Page: 1 2 3 4 

Top

Related drugs of malignant transformation related genes

check buttonIdentification of chemicals and drugs interact with genes involved in malignant transfromation
(DGIdb 4.0)
Entrez IDSymbolCategoryInteraction TypesDrug Claim NameDrug NamePMIDs
3276PRMT1ENZYME, METHYL TRANSFERASEFURAMIDINEFURAMIDINE24564570
3276PRMT1ENZYME, METHYL TRANSFERASENSC-45174CHEMBL22104720666457
3276PRMT1ENZYME, METHYL TRANSFERASEinhibitor310264736
3276PRMT1ENZYME, METHYL TRANSFERASEinhibitor178103616
3276PRMT1ENZYME, METHYL TRANSFERASEinhibitor178103608
3276PRMT1ENZYME, METHYL TRANSFERASEinhibitor178103607
3276PRMT1ENZYME, METHYL TRANSFERASESTILBAMIDINESTILBAMIDINE20666457
3276PRMT1ENZYME, METHYL TRANSFERASENSC-47762CHEMBL109274020666457
3276PRMT1ENZYME, METHYL TRANSFERASEEOSINEOSIN18348515
Page: 1